Anthropic said the company's life science team is working to speed up research and development of disease cures. Over the past few months, Anthropic researchers have carried out in-depth research collaborations with six new drug development institutions. Partners include BigHat Biosciences, Bristol-Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. At the same time, Anthropic has also launched its own drug discovery program. In addition to cooperating with the above partners, Anthropic also independently operates a self-developed pipeline. Anthropic has acquired Mithril Medicine, a single-person startup focused on developing treatments for two rare muscular dystrophies. Founder Cody Tranbarger relied on Claude to coordinate contracts, logistics, and connect with 11 external laboratories to conduct experiments, leaving a large number of operations to Claude.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.